title: Novel combinations for the treatment of metastatic breast cancer.
abstract: Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anthracyclines and taxanes. Other options have limited data to support their use in this setting but are commonly used in practice. Future MBC therapies will likely combine alternative chemotherapies and novel biologic agents, and numerous ongoing trials should help to further define the proper use of these regimens.
authors.affiliation: Weill Cornell Medical College, 425 East 61st Street, 8th Floor, New York, NY 10065, USA. ltv2001@med.cornell.edu.
authors.forename: Linda T
authors.initials: LT
authors.lastname: Vahdat